HUMAW — Humacyte Inc
NASDAQ
$0.00
-$0.00 (-19.61%)
Humacyte Inc (HUMAW) common stock listed on NASDAQ. It is led by Laura E. Niklason M.D., Ph.D., based in 2525 East North Carolina Highway 54, Durham, NC, United States, 27713, with about 184 employees. Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Latest reported HUMAW revenue for 2025-09-30 was $753.0K. Net income was -$17.5M. Revenue was up 150.2% from 2025-06-30 to 2025-09-30.
Use this HUMAW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the HUMAW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the HUMAW SEC filings page. Lician reads the product cache first so this HTML stays unique to Humacyte Inc even when a live quote feed is slow.
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
HUMAW Key Statistics
Market Cap
$0.00M
Volume
58,663
Previous Close
$0.01
Day Range
$0.00 – $0.01
EPS
-$1.26
Revenue
$0.00
Net Income
-$148.70M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
184
HUMAW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$148.70M | -$110.78M | -$11.96M | -$26.48M |
| EPS (Diluted) | -$1.26 | -$1.07 | -$0.12 | -$0.66 |
Total Assets
$137.87M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$44.94M
Operating Cash Flow
-$98.12M
Free Cash Flow
$0.00
Humacyte Inc Company Information
- Founder, President, CEO & Director
- Laura E. Niklason M.D., Ph.D.
- Headquarters
- 2525 East North Carolina Highway 54, Durham, NC, United States, 27713
- Website
- www.humacyte.com
- Phone
- 919 313 9633
- IPO / Founded
- 2020-11-24